Here's Why You Should Hold DaVita Stock in Your Portfolio for Now

DaVita (DVA), market cap ~$8.33B, reported mixed Q3 2025 results with sequential growth in revenue and revenue-per-treatment but a year-over-year decline in EPS; the company served ~293,200 patients at 3,247 outpatient centers (2,662 U.S., 585 international), opened 3 U.S. centers and acquired 58 international centers in Q3. Management projects 12.6% growth over the next five years; Zacks consensus for full-year 2025 EPS is stable at $10.52, Q4-2025 revenue is estimated at $3.53B (+6.9% YoY) while Q4 EPS consensus of $3.34 implies a 49.1% YoY decline — key downside remains exposure to commercial payers and potential margin pressure from shifts to government reimbursement.

Analysis

Market structure: DaVita (DVA, market cap ~$8.3bn) benefits from scale in integrated kidney care and faster international center add-ons (58 centers Q3), while commercial payers, Medicare Advantage growth and price-sensitive independent centers are losers. Expect pricing pressure in U.S. dialysis as commercial mix drops; international expansion improves revenue growth but is capital-intensive and slower to convert to margin (6–18 months lag). Cross-asset: sustained margin squeeze would raise credit spreads for DVA paper and increase equity implied volatility; healthcare defensives (ISRG, MEDP, BSX) should see relative inflows.

Risk assessment: Tail risks include abrupt CMS reimbursement cuts or accelerated MA conversion compressing EBITDA by >15% in 12 months, or a material JV/partner dispute impairing operations in key states; low-probability but high-impact. Near-term (days–weeks) triggers: MA enrollment cadence (Oct–Dec) and Q4 guidance; medium-term (3–12 months): CMS rulemaking and CMMI pilot results; long-term: home-dialysis adoption and international integration (12–36 months). Hidden dependencies: profitability hinges on commercial mix, JV minorities and acquisition integration costs.

Trade implications: Tactical short bias in DVA sized 1–3% notional via 3–6 month 10–20% OTM put spreads to cap cost ahead of Q4 (consensus EPS $3.34, rev $3.53bn) and MA enrollment; pair trade long BSX or ISRG (1–2% long) vs short DVA to capture sector rotation into higher-growth device/CRO names. If volatility spikes, sell DVA covered calls against existing long or buy protective collars. Reallocate 2–4% from dialysis names into MEDP/ISRG for superior earnings consistency.

Contrarian angles: Consensus is underweight the international inorganic growth runway — if management converts new centers to normalized EBITDA within 9–12 months, DVA could re-rate; this is underappreciated given recent center buys. Conversely, market may be underpricing persistent margin degradation from MA; the optimal hedge is dynamic (trim/extend) around CMS milestones rather than static buy-and-hold.

Key Decisions for Investors

• Establish a 1–3% portfolio short position in DVA using 3–6 month put spreads sized to risk tolerance (buy 10–20% OTM put / sell 30% OTM put) ahead of MA enrollment close and Q4 results; close or reassess after Q4 print if EPS beats by >10% or international margins show clear inflection.
• Initiate a 1–2% long allocation to ISRG or MEDP (split 60/40) as sector rotation plays—these have cleaner earnings beats and 15–17% LT growth; add on >5% pullback or after DVA weakness confirms payer-driven rotation.
• Execute a relative-value pair: long 1% BSX (or ISRG) vs short 1% DVA to express device/CRO outperformance vs dialysis, monitor spread weekly and close if spread narrows <5% or macro healthcare flows reverse.
• If holding DVA equity, purchase a 9–12 month collar (buy 12–15% OTM put, sell 20–25% OTM call) to protect from >10–15% downside through next CMS/MA headlines while retaining limited upside participation.
• Reduce direct exposure to dialysis group names by 30–50% of current position sizes within 1 month if MA enrollment share rises >200bps quarter-over-quarter or if consensus 2026 EBITDA revisions turn negative by >10%.